News | August 25, 2025
Enanta files patent infringement suit against Pfizer
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The facility will be positioned as a Centre of Excellence for tertiary care services
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Subscribe To Our Newsletter & Stay Updated
